Condition: Idiopathic Pulmonary Fibrosis · Sponsor: Trevi Therapeutics
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
This description comes directly from the study's public registry record.
Connie Crum · 203-654-3287 · Connie.crum@trevitherapeutics.com
Paula Buckley · 203-680-3864 · Paula.buckley@trevitherapeutics.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Medicines Evaluation Unit Ltd. | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07036029